Trial protocol of Rett gene therapy now only using low dose: Developer
The protocol of the Phase 1/2 trial (NCT05898620) that’s evaluating Neurogene’s NGN-401 in girls with Rett syndrome has been amended to use the low treatment dose of the gene therapy for all future participants, the company announced. The protocol alteration was submitted to the U.S.  Food and Drug…